Farxiga (dapagliflozin) is an oral medication primarily used to:
1. Manage Type 2 Diabetes
Mechanism: It’s an SGLT2 (sodium-glucose cotransporter-2) inhibitor. It works by blocking glucose reabsorption in the kidneys, causing excess sugar to be excreted in urine.
Effect: Lowers blood sugar levels, reduces HbA1c, and promotes weight loss (typically 2–4 kg).
2. Protect Heart & Kidneys (Key Long-Term Benefits)
- Heart Failure
- Approved to reduce hospitalization and death in adults with heart failure (both with and without diabetes).
- Improves heart function and symptoms like fatigue/swelling.
Chronic Kidney Disease (CKD)
- Slows kidney damage progression and lowers risk of kidney failure/dialysis in diabetic and non-diabetic CKD patients.
Cardiovascular Protection:
- Reduces risk of heart attack/stroke in people with type 2 diabetes and existing heart disease.
3. Other Approved Uses
-Type 1 Diabetes (in some countries):
- Adjunct to insulin (requires careful monitoring due to DKA risk).
- Non-Alcoholic Fatty Liver Disease (NAFLD):
- Emerging evidence suggests benefits for liver fat reduction (though not yet FDA-approved for this).
Important Consideration
Side Effects:
- Genital yeast infections (common).
- Urinary tract infections (UTIs).
- Diabetic Ketoacidosis (DKA):Rare but serious (monitor for symptoms like nausea, abdominal pain, confusion).
- Dehydration/low blood pressure.
Who Should Avoid It?
- People with severe kidney impairment (eGFR <25).
- Type 1 diabetics (unless prescribed off-label with strict safeguards).
- History of Fournier’s gangrene or hypersensitivity.
How It Compares to Metformin
- Metformin (first-line for diabetes) improves insulin sensitivity.
- Farxiga offers -unique organ protection- (heart/kidneys) beyond glucose control.
- Often prescribed *with* metformin for additive benefits.
If you’re considering Farxiga for diabetes, heart failure, or kidney protection, consult your doctor to discuss suitability and monitoring. Need clarification on a specific use case?
Comments
Post a Comment